Recent Press Releases

CSL to acquire Novartis' influenza vaccine business

Melbourne, Australia — 27/10/2014 CSL Limited has today announced an agreement to acquire Novartis' global influenza vaccine business for US$275 million, which will be combined with...

Valeant Delivers Letter To Allergan Board

10/27/2014 · Prepared to Improve Offer And Provide Value of at Least $200 a Share · Urges Allergan Board to Take Control of Process LAVAL, Quebec, Oct. 27, 2014 /PRNewswire/...

CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis, strengthening mortality benefit and reinforcing safety profile

CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis, strengthening mortality benefit and reinforcing safety profile Pooled analysis of ASCEND and two CAPACITY phase III trials...

Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million

Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million...

Novo Nordisk receives subpoena from US Attorney

Novo Nordisk receives subpoena from US Attorney Bagsværd, Denmark 24 October 2014 - Novo Nordisk today announced that it has been served with a subpoena by the office of the US Attorney for the...

Pfizer Wins SUTENT® Patent Case In Delaware District Court

Pfizer Wins SUTENT® Patent Case In Delaware District Court Oct. 23, 2014 - Pfizer Inc. announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the...

Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results

Posts Third Quarter GAAP EPS of $0.43 and Non-GAAP EPS of $0.45 Achieves Significant Regulatory Milestones for PD-1 Inhibitor Opdivo Launches Daklinza-Based Regimens for HCV Patients in Japan and...

Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend

Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend The board of directors of Pfizer Inc. today declared a 26-cent fourth-quarter 2014 dividend on the company's common stock, payable December 2,...

Amgen Announces Webcast of 2014 Third Quarter Financial Results

THOUSAND OAKS, Calif., Oct.

Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014

FREMONT, Calif., Oct. 23, 2014 /PRNewswire/ -- Ardelyx, Inc.

The Hope Murals Project National Art Movement Culminates in Painting Event at Grand Central Terminal on October 23

Lilly Oncology On Canvas Art Competition Names 2014 Winners; E!

Lilly Reports Third-Quarter 2014 Results

INDIANAPOLIS, Oct. 23, 2014 /PRNewswire/ --

NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack

In draft guidance published today for consultation, NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare) as an option for preventing blood clots in people who have had a heart attack as a...

LEADING RESEARCHERS JOIN BIOGEN IDEC TO ADVANCE DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

–Christopher Henderson and Richard Ransohoff to Lead and Enhance the Company's Neurology Research and Discovery Effort– CAMBRIDGE, Mass., October 23, 2014, Biogen Idec (NASDAQ: BIIB)...

Lilly Reports Third-Quarter 2014 Results

Lilly Reports Third-Quarter 2014 Results INDIANAPOLIS, Oct. 23, 2014 /PRNewswire/ -- Third-quarter 2014 revenue declined 16 percent driven by the impact of U.S. patent expirations for Cymbalta and...

Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent

Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent DUBLIN, Oct. 23, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal...

Celgene Reports Third Quarter 2014 Operating and Financial Results

Celgene Reports Third Quarter 2014 Operating and Financial Results - 2014 Total Revenue and Adjusted Diluted EPS Guidance Raised - Phase II Data on GED-0301 Presented at United European...

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies

INDIANAPOLIS and

Abbott Reports Third-Quarter 2014 Results

- Third-Quarter Adjusted EPS Above Previous Guidance Range, Including Results From Discontinued Operations Related to Mylan Transaction -

ABBOTT PARK, Ill.,